Drug profile · INN
spinosad
NATROBA
spinosad (NATROBA) is a nicotinic acetylcholine receptor agonist. Route of administration: topical. Current US regulatory status: approved.
Drug details — spinosad
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
spinosad (NATROBA) is a nicotinic acetylcholine receptor agonist. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Nicotinic acetylcholine receptor agonist
Primary target: Nicotinic acetylcholine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is spinosad?
spinosad (NATROBA) is a nicotinic acetylcholine receptor agonist. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for spinosad?
NATROBA is a marketed brand name for spinosad. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of spinosad?
spinosad has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.